Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTC-1202
- Development stage
- Preclinical
- Lead developer
- Phoenix SENOLYTIX
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous
01
Overview
PTC-1202 is a proprietary small molecule formulation of rimiducid being developed by Phoenix SENOLYTIX as a chemical inducer of dimerization (CID). It is specifically designed to activate the ApoptiCIDe platform, which utilizes an inducible caspase-9 (iCasp9) switch for regulated gene therapy applications, including purposeful cell elimination (ApoptiCIDe-CE) and regulated gene expression (ApoptiCIDe-RGT). Unlike the original intravenous formulation of rimiducid developed by Bellicum Pharmaceuticals, which required a 2-hour infusion, PTC-1202 is formulated for intramuscular or subcutaneous administration, potentially allowing for more convenient delivery via an autoinjector pen. The drug is currently in preclinical development for applications in aging-related disorders and obesity-related conditions.
- Other names
- ApoptiCIDe DimerizerApoptiCIDe™ Dimerizerrimiducid IM/SubQ formulation
02
Targets
iCasp9 (Inducible caspase-9)
Beyond the preview
Go deeper on PTC-1202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTC-1202.